| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/321395/2013 (30.05.13) |
| Publication Date | 30/05/2013 |
| Content Type | News |
|
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), in May 2013, recommended restricting the use of the anti-epileptic medicine Trobalt (retigabine) only to those patients for whom other anti-epileptic medicines had proved inadequate or had not been tolerated. This followed a careful evaluation of cases of pigmentation (abnormal colouring) of the skin, nails, lips and eye tissues, including the retina (the light sensitive layer at the back of the eye) reported in patients taking part in long-term studies. |
|
| Source Link | Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/05/news_detail_001802.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
